Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy

Click to increase image sizeClick to decrease image size

Authors’ contributions

SH and KES designed and planned the study. SH, KES, SEl and SEk managed the data collection. SH and SEl performed the statistical analyses. SH and KES interpreted the data and wrote a manuscript draft. All authors contributed with interpretation of data and approved the final version of the manuscript.

Disclosure statement

P-OA joined the speaker’s bureau of AbbVie, Astra Zeneca, Gilead, Janssen, and Roche and has been a consultant for Abbvie, Beigene, Incyte, Janssen, Sandoz and Takeda. GE: Lectures for Roche and Pierre Fabre. Advisory board for Pierre Fabre and Gilead. SH, SEl, SEk, KS, ML, BS and MJ have no disclosures.

Additional information

Funding

This data collection was funded partly through grants from the Swedish Cancer Society [grant no 200705] and partly through the public-private research partnership between Karolinska Institutet and Janssen Pharmaceutica NV (Ref: 5-63/2015). The funding bodies supported the data collection but did not have a role in the study design, data analyses or manuscript writing/decision to publish.